Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00820404 |
The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: BLI-489 Drug: Placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety Study |
Official Title: | Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects |
Estimated Enrollment: | 56 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
BLI-489
|
Drug: BLI-489 |
2: Placebo Comparator
Placebo
|
Drug: Placebo |
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) ) |
Study ID Numbers: | 3219K1-1000 |
Study First Received: | January 9, 2009 |
Last Updated: | March 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00820404 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Healthy |